Exploring Providers' Behaviors, Attitudes, and Preferences on the Treatment of Pulmonary Arterial Hypertension With Endothelin Receptor Antagonist (ERA) + Phosphodiesterase‐5 Inhibitors (PDE5i)

Exploring Providers' Behaviors, Attitudes, and Preferences on the Treatment of Pulmonary Arterial Hypertension With Endothelin Receptor Antagonist (ERA) + Phosphodiesterase‐5 Inhibitors (PDE5i)

ABSTRACT This study aims to understand healthcare providers' (HCPs) decision to adopt double combination therapy with ERA + PDE5i for pulmonary arterial hypertension (PAH), and to explore whether a single tablet combination therapy (STCT) might increase adoption practices. 195 US HCPs completed...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicholas A. Kolaitis, Martha Kingman, Melisa Wilson, Gabriela Gomez Rendon, David Lopez, Carly J. Paoli, Mohammad Rahman, Ashley Martin, November McGarvey, Abraham Lee, Lana Melendres‐Groves
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Pulmonary Circulation
Subjects:
combination therapy
ERA
PDE5i
pulmonary arterial hypertension
treatment preferences
Online Access:https://doi.org/10.1002/pul2.70113
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/pul2.70113

Similar Items